Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease.
Novartis and the Bill has announced its collaboration with Melinda Gates Foundation to discover and develop an accessible in vivo gene therapy, thus a new method of gene therapy to cure Sickle Cell Disease (SCD).
A press release issued by the Sickle Cell Foundation of Ghana indicated that the agreement with the foundation will provide funding support for the discovery and development of a single-administration.










